COMPREHENSIVE ANALYSIS OF DNA COPY NUMBER VARIATIONS AND GENE EXPRESSION IN OSTEOSARCOMA Nalan Gokgoz, Atta Goudarzi, Cheryl Wolting Jay S. Wunder and.

Slides:



Advertisements
Similar presentations
Early Embryonic Development Maternal effect gene products set the stage by controlling the expression of the first embryonic genes. 1. Transcription factors.
Advertisements

Acquisition of tumour multidrug resistance inevitable in most advanced solid tumours – Failing to cure the majority of advanced solid tumours – Declining.
Yan Guo Assistant Professor Department of Cancer Biology Vanderbilt University USA.
Polymorphisms: Clinical Implications By Amr S. Moustafa, M.D.; Ph.D. Assistant Prof. & Consultant, Medical Biochemistry Dept. College of Medicine, KSU.
Cancer Genetics Is Cancer a Genetic Disease? Cancer is not a classic genetic disease, instead, Genetic background (set-up) has a definite role in cancer.
Gene regulation in cancer 11/14/07. Overview The hallmark of cancer is uncontrolled cell proliferation. Oncogenes code for proteins that help to regulate.
EXPRESSION OF EZRIN mRNA AND PROTEIN IN OSTEOSARCOMA: RELATIONSHIP TO PATIENT CLINICAL CHARACTERISTICS Taiqiang Yan, Rita Kandel, Nalan Gokgoz, Robert.
NF2: A Tumor Suppressor NF2 encodes Merlin/Schwannomin, a protein that regulates cell growth and proliferation.
By: Katie Adolphsen, Robin Aldrich, Brandon Hu, Nate Havko.
Comparative Genomic Hybridization (CGH). Outline Introduction to gene copy numbers and CGH technology DNA copy number alterations in breast cancer (Pollack.
 MicroRNAs (miRNAs) are a class of small RNA molecules, about ~21 nucleotide (nt) long.  MicroRNA are small non coding RNAs (ncRNAs) that regulate.
Office hours Wednesday 3-4pm 304A Stanley Hall Review session 5pm Thursday, Dec. 11 GPB100.
Multi-dimensional Genomic Profiling of Acute Leukemias Characterized by MLL gene rearrangements Eunice S. Wang MD (Medicine) and Norma J. Nowak PhD (Cancer.
Presented by Karen Xu. Introduction Cancer is commonly referred to as the “disease of the genes” Cancer may be favored by genetic predisposition, but.
Paola CASTAGNOLI Maria FOTI Microarrays. Applicazioni nella genomica funzionale e nel genotyping DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE.
Supplementary Figure 1. Somatic mutation spectrum # Substitutions # Substitutions per Mb b c a Repeats Pseudogenes Whole genome Splice sites Non-coding.
Cytoplasmic Signaling Circuitry Programs Many of the Traits of Cancer
Malignant Melanoma and CDKN2A
Large-Scale Copy Number Polymorphism in the Human Genome J. Sebat et al. Science, 305:525 Luana Ávila MedG 505 Feb. 24 th /24.
Genetic Alterations of TP53 Gene in Brain Astrocytic Tumours Methodology Θ Eighty-three brain tumor biopsies were collected and used in this study. Thirty.
Amplification of COPS3 in High-grade Osteosarcoma: Relationship to TP53 Mutation and Patient Outcome Samuel Lunenfeld Research Institute Mount Sinai Hospital,
3.1.3.A Understanding Cancer What is Cancer.
Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.
Understanding Cancer. What Is Cancer? Different Kinds of Cancer Lung Breast (women) Colon Bladder Prostate (men) Some common sarcomas: Fat Bone Muscle.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Genetics-multistep tumorigenesis genomic integrity & cancer Sections from Weinberg’s ‘the biology of Cancer’ Cancer genetics and genomics Selected.
Nalan Gokgoz, Taiqiang Yan, Michelle Ghert, Mona Gill, Shelley B Bull, Robert S Bell, Jay S Wunder, Irene L Andrulis Mount Sinai Hospital and Samuel Lunenfeld.
CONTEXT SPECIFIC ROLE OF DEUBIQUITYLASE ENZYME, USP9X, IN HEAD AND NECK CANCER Devathri Nanayakkara Eskitis Institute for Drug Discovery Griffith University.
The ERK- MAP Kinase-PEA3-MMP-1 axis is operative in Oesophageal Adenocarcinoma Yeng Ang Consultant Gastroenterologist, Salford Royal University NHS FT.
Characteristics of Cancer. Promotion (reversible) Initiation (irreversible) malignant metastases More mutations Progression (irreversible)
©Edited by Mingrui Zhang, CS Department, Winona State University, 2008 Identifying Lung Cancer Risks.
YUEMIN DING Neuro-oncology Group Department of Molecular Neuroscience
Poster Discussion 2 - Biology Genome Transcriptome Proteome Metastasome.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Marco Magistri , Journal Club. A non-coding RNA (ncRNA) is any RNA molecule that is not translated into a protein “Structural genes encode proteins.
Apostolos Zaravinos and Constantinos C Deltas Molecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, Department of Biological.
SP Cancer Metastasis Summary Hypothesis: We hypothesize that miRNAs regulate breast cancer cell invasiveness and metastasis by synergistically targeting.
Problem 1 James is the only person in his kindred affected by DMD. He has one unaffected brother, Joe. DNA analysis show that James has a deletion in the.
Genetics of Cancer Genetic Mutations that Lead to Uncontrolled Cell Growth.
Copy Number Variation Eleanor Feingold University of Pittsburgh March 2012.
____ __ __ _______Birol et al :: AGBT :: 7 February 2008 A NOVEL APPROACH TO IMPROVE THE NOISE IN DETECTING COPY NUMBER VARIATIONS USING OLIGONUCLEOTIDE.
Maxwell Lee National Cancer Institute Center for Cancer Research High-dimension Data Analysis Group March 19, 2014 Integrated Studies Of Breast, Esophageal,
Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.
PREDICTING OUTCOME IN OSTEOSARCOMA USING A GENOME-WIDE APPROACH N Gokgoz,T Yan, M Ghert, S Eskandarian W He, R Parkes, SB Bull, RS Bell, IL Andrulis and.
Lecture 11. Topics in Omic Studies (Cancer Genomics, Transcriptomics and Epignomics) The Chinese University of Hong Kong CSCI5050 Bioinformatics and Computational.
Gene Sleuthing Lorraine Sartori Majid Masso Paul R. McCreary.
Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.
CBioPortal Web resource for exploring, visualizing, and analyzing multidimentional cancer genomics data.
TSC1/Hamartin and Facial Angiofibromas Biology 169 Ann Hau.
YEATS4 Is a Novel Oncogene Amplified in Non– Small Cell Lung Cancer That Regulates the p53 Pathway Speaker:Dai-Wei Hsuan Adviser:Dr. Guor-Mour, Her Data:2015/04/22.
Different microarray applications Rita Holdhus Introduction to microarrays September 2010 microarray.no Aim of lecture: To get some basic knowledge about.
Cancer Bioinformatics Tom Doman Bioinformatics Scientist Eli Lilly & Company Informatics 519 guest lecture IU Bloomington Sept
Tumor-suppressor genes Tumor-suppressor genes, function like brakes, keep cell numbers down, either by inhibiting progress through.
EUKARYOTIC CELL SIGNALING VII Abnormal Signaling in Cancer Signaling to p53 Dr. Ke Shuai Office: 9-240M Factor Tel: X69168
1 Finding disease genes: A challenge for Medicine, Mathematics and Computer Science Andrew Collins, Professor of Genetic Epidemiology and Bioinformatics.
Colon cancer: the second leading cause of cancer deaths in the U.S. Polyps, the first stage In tumor development
GENETIC BIOMARKERS.
Controls the Cell Cycle
B lymphocytes produce antibodies.
Loyola Marymount University
Figure 24.1 Phases of the cell cycle.
Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma
M.B.Ch.B, MSC, PhD, DCH (UK), MRCPCH
Genetic landscape of salivary duct carcinoma.
Identification and characterization of a novel KRAS rearrangement in metastatic prostate cancer. Identification and characterization of a novel KRAS rearrangement.
Loyola Marymount University
Loyola Marymount University
Loyola Marymount University
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours By: Anh Pham.
Loyola Marymount University
Presentation transcript:

COMPREHENSIVE ANALYSIS OF DNA COPY NUMBER VARIATIONS AND GENE EXPRESSION IN OSTEOSARCOMA Nalan Gokgoz, Atta Goudarzi, Cheryl Wolting Jay S. Wunder and Irene L. Andrulis Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital Toronto, ON, Canada. Connective Tissue Oncology Society Meeting November 1, 2013

High resolution approaches to identify genes and pathways predictive of outcome in OS  Gene expression profiling by Microarray Analysis  Identification of the most relevant biological pathways for list of discriminative genes by Ingenuity Pathway Analysis  Identification of the significant effectors and organizing networks in OS metastasis by Dynamo (Taylor and Chuang)  Interrogation of biological pathways and networks  Investigation of Copy Number Changes by Illumina SNP array technology  Detection and characterization of alterations  Analysis and visualization by Genome Studio and GAP  Identification of significant recurrent targets by GISTIC Identification and Characterization of Molecular Alterations Identification and Characterization of Molecular Alterations in Osteosarcoma in Osteosarcoma

High-grade Intramedullary 63 patients No Metastasis at Diagnosis 46 patients Metastasis at Diagnosis 17 patients No Metastasis 4 years post Dx. (29 patients) Metastasis within 4 years Dx. (17 patients) AB A1 A2 PATIENT COHORT

No Metastases 4 years post Dx (A1) vs Metastases within 4 years Dx (A2) No Metastases 4 years post Dx (A1) vs Metastases within 4 years Dx (A2) cDNAs T-statistic p<0.001 (BrB Array Tools) n=53 genes for tumor classification/clustering Statistical validation by Leave-One Out cross-validation method Molecular validation by Real-Time Analysis Outcome of the Patients Presenting with “no Metastases” No Mets. 4 yrs post Dx. Mets. within 4 yrs post Dx. MICROARRAY ANALYSIS MICROARRAY ANALYSIS

Gene A Gene C. Gene X Gene Y Interactions and Relationships between molecules in set Networks Pathways with which molecules in set are associated Pathways Functions with which molecules in set are associated Functions Upstream regulators that may be responsible for observed increase/decrease in expression Upstream Regulators Molecule Set Ingenuity Pathway Analysis

Summary of IPA in OS metastasis Networks cell morphology, organization, hematopoiesis Pathways Rac/Rho, actin cytoskeleton Functions hematopoiesis, cell movement Regulators Fas, Fos, SP1, SREBF1

Signaling by Rho Family GTPases Lower expression in A2 Higher expression in A2 A1 – No mets A2 – Mets in 4 yrs

GENETIC NETWORKS in OS METASTASIS The PRKCε, RASGPR3 and GNB2 networks differentially activated DLG2 network differentially organized The PRKCε, RASGPR3 and GNB2 networks are potential effectors of DLG2 Significant Networks Transport Translation Signaling Protein Kinase C Epsilon and Genetic Networks in Osteosarcoma Metastasis; A Goudarzi, N Gokgoz, M Gill, D Pinnaduwage, D. Merico, J.S Wunder and IL Andrulis, Cancer, 2013, 5,

Osteosarcoma and Copy Number Alterations  Illumina 610-Quad Whole-genome genotyping beadchip  Coverage includes >14,000 CNV regions and 550K evenly spaced TagSNPs from HapMap data  High Resolution: Spacing 2.7 kb  Includes markers in the unSPNable Genome  Allows detection of SNPs, Copy Number Variation and Genotype  Reference Genotype: Canonical genotype clusters (200 HapMap DNA genotype data)  44 Osteosarcoma Tumor DNA  Validation by Real Time PCR  25 of them with matched blood DNA

Complexity of OS Tumour Genome (Analysis by Genome Studio) Blood DNA Tumour DNA Allele Frequency BBABAA LogR Ratio

OS-2550_Chromosome 3 Genome Alteration Print (GAP) Analysis

COL12A1 COL9A1 AF CDK4 MDM2 COL4A1 COL4A2 LIG4 MYR8 COPS3 NCORI PMP22 PPFIBP1 FGFR1OP2 Recurrent Copy Number Gains in OS identified by GISTIC (Genome Identification of Significant Targets in Cancer) * * * * Same family genes q value

Recurrent Copy Number Losses in OS identified by GISTIC LOC CNTNAP2 CDKN2A MTAP DLG2 RB1 TP53 GRIK2 * * * DOCK5 * Same family genes q value NAALADL2

11q14.1 deletion in a matched tumor-blood DNA DLG2

 One of the most disorganized genetic networks in metastatic OS tumours.  The PRKCε, RASGPR3 and GNB2 networks are potential effectors of DLG2  Tumour suppressor function of dlg2 in Drosophila  Scribble complex (SCRIB, DLG1-4 and LGL1/2) deregulation in Prostate Cancer  DLG2 implicated in Wilms Tumour Implication of DLG2 as a tumour suppressor in cancer

DLG2 (discs, large homolog 2) Channel associated protein of synapse 110 Chromosome 11q14 Member of the membrane-associated guanylate kinase (MAGUK) family. PDZ domains; interaction with signalling proteins at postsynaptic sites SH3 domains are found in proteins of signaling pathways regulating the cytoskeleton and regulate the activity state of adaptor proteins and other tyrosine kinases GuKinase Domain; catalyzes ATP-dependent phosphorylation of GMP to GDP Gene: 2 MB, 33 alternative spliced transcripts Longest transcript :3.7KB, 26 Exons Expression site: Brain, hypothalamus

Relative Expression of DLG2 in OS tumours and cell-lines Deletion of DLG2 gene detected by SNP array

 SiRNA Knockdown of the DLG2 Gene in U2OS 70% knockdown at 72 hours Work in Progress  The effect of DLG2 knockdown in  Cell viability and growth by XTT assay  Migration by scratch assay  Sequencing of DLG2 gene for inactivating mutations

 We identified a 53-gene expression signature that may predict outcome of OS patients with localized tumours.  High-resolution approaches identified candidate pathways and networks that may be biologically relevant in OS.  Cell morphology and organization pathways may be involved in OS metastasis.  A large number of chromosomal aberrations were detected in OS tumours by SNP array technology.  The DLG2 gene that is deleted in 20 percent of the OS cases and belonging to a significantly disorganized metastatic OS network and was chosen for further functional analysis.  Further experiments will be performed to investigate the functional role of DLG2 in cell growth, proliferation and migration. CONCLUSION

Acknowledgement Mount Sinai Hospital Orthopedic Surgeons Hospital for Sick Children D.Malkin Vancouver General Hospital C.Beauchamp R. Kandel University of Washington E.Conrad III Royal Orthopedic Hospital R.Grimer Memorial Sloan-Kettering J.Healey Mayo Clinic M.Rock/ L.Wold Andrulis and Wunder Lab S. Bull R. Parkes I. Andrulis J. Wunder Andrew Seto

During progression from tumour growth to metastasis, specific integrin signals enable cancer cells to detach from neighbouring cells, re-orientate their polarity during migration, and survive and proliferate in foreign microenvironments. There is increasing evidence that certain integrins associate with receptor tyrosine kinases (RTKs) to activate signalling pathways that are necessary for tumour invasion and metastasis. The effect of these integrins might be especially important in cancer cells that have activating mutations, or amplifications, of the genes that encode these RTKs.